Spots Global Cancer Trial Database for Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
Official Title: A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma
Study ID: NCT00471367
Interventions
Study Description
Brief Summary: This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a twice a week basis. For Part B, an additional 20 patients will be treated at the maximum dose identified in Part A. AZD4877 is an Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, New York, New York, United States
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Greenville, South Carolina, United States
Contact Details
Name: Jeffrey Skolnik, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Lea Burke
Affiliation: AstraZeneca
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
